Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Utility of brain volumetry and tissue integrity in MS diagnosis

Jaume Sastre-Garriga, MD, PhD, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, discusses the utility of brain volumetry in the monitoring of multiple sclerosis (MS) and its implementation in clinical practice. Brain volumetry reflects changes in brain atrophy and can therefore be utilized to facilitate the prediction of clinical outcomes and to assess treatment responses. Currently, new systems are being developed and put into place to overcome the challenges presented by the required mechanisms of brain volumetry. Dr Sastre-Garriga explains that upon the implementation of these systems as standard in clinical practice, brain volumetry will be a valid tool in disease monitoring. Compared to other markers of tissue integrity, such as T1/T2 ratio and lesion parameters, brain volumetry has the most potential for clinical utility, however, further research into the widespread applications and standardization of this tool is needed. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

Disclosures

Dr. J. Sastre-Garriga has participated in the last twelve months in events organized by BMS, Merck, Sanofi, Roche and BIOGEN; Dr. J. Sastre-Garriga is Scientific Director of Revista de Neurología, and co-Editor for Europe of the Multiple Sclerosis Journal.